0001140361-23-042366.txt : 20230901
0001140361-23-042366.hdr.sgml : 20230901
20230901160707
ACCESSION NUMBER: 0001140361-23-042366
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230831
FILED AS OF DATE: 20230901
DATE AS OF CHANGE: 20230901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GNI Group Ltd.
CENTRAL INDEX KEY: 0001958461
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51173
FILM NUMBER: 231232548
BUSINESS ADDRESS:
STREET 1: NIHONBASHI-HONCHO YS BLDG 3F
STREET 2: 2-2-2 NIHONBASHI-HONCHO, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-0023
BUSINESS PHONE: 81-3-6214-3600
MAIL ADDRESS:
STREET 1: NIHONBASHI-HONCHO YS BLDG 3F
STREET 2: 2-2-2 NIHONBASHI-HONCHO, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-0023
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GNI Hong Kong Ltd
CENTRAL INDEX KEY: 0001958509
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51173
FILM NUMBER: 231232547
BUSINESS ADDRESS:
STREET 1: 12/F ELITE CENTRE
STREET 2: 22 HUNG TO ROAD
CITY: KWUN TONG KL
STATE: K3
ZIP: 0000
BUSINESS PHONE: 81-3-6214-3600
MAIL ADDRESS:
STREET 1: 12/F ELITE CENTRE
STREET 2: 22 HUNG TO ROAD
CITY: KWUN TONG KL
STATE: K3
ZIP: 0000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CATALYST BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001124105
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562020050
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 710
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-871-0761
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 710
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: TARGACEPT INC
DATE OF NAME CHANGE: 20000919
4
1
form4.xml
X0508
4
2023-08-31
0001124105
CATALYST BIOSCIENCES, INC.
CBIO
0001958461
GNI Group Ltd.
NIHONBASHI-HONCHO YS BLDG 3F
2-2-2 NIHONBASHI-HONCHO, CHUO-KU
TOKYO
M0
103-0023
JAPAN
true
0001958509
GNI Hong Kong Ltd
12/F ELITE CENTRE
22 HUNG TO ROAD
KWUN TONG KL
K3
HONG KONG
true
false
Series Y Preferred Stock
2023-08-31
4
D
0
895.217
D
0
D
Series Y Preferred Stock
2023-08-31
4
D
0
5371.303
D
0
D
On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.
On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated.
These securities are held by GNI Group Ltd. ("GNI Japan").
GNI Hong Kong Ltd. ("GNI HK") disclaims beneficial ownership of the securities held by GNI Japan for purposes of Rule 16a-1(a)(2), except to the extent of its pecuniary interest therein.
These securities are held by GNI HK.
GNI HK, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI HK and, therefore, a "ten percent holder" hereunder.
/s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.
2023-09-01
/s/ Branden Berns, as attorney-in-fact for GNI Hong Kong Ltd
2023-09-01